Hollow Brook Wealth Management LLC decreased its holdings in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 9.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 178,823 shares of the biopharmaceutical company’s stock after selling 17,982 shares during the period. Pfizer comprises 0.9% of Hollow Brook Wealth Management LLC’s portfolio, making the stock its 20th biggest holding. Hollow Brook Wealth Management LLC’s holdings in Pfizer were worth $5,100,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also modified their holdings of the company. TOWER TRUST & INVESTMENT Co grew its position in Pfizer by 1.9% in the third quarter. TOWER TRUST & INVESTMENT Co now owns 19,322 shares of the biopharmaceutical company’s stock valued at $551,000 after acquiring an additional 357 shares during the period. Angeles Wealth Management LLC lifted its holdings in shares of Pfizer by 2.2% during the second quarter. Angeles Wealth Management LLC now owns 17,009 shares of the biopharmaceutical company’s stock valued at $410,000 after acquiring an additional 358 shares during the period. Manchester Financial Inc. boosted its stake in shares of Pfizer by 2.9% in the 2nd quarter. Manchester Financial Inc. now owns 13,168 shares of the biopharmaceutical company’s stock valued at $317,000 after purchasing an additional 365 shares in the last quarter. Delta Financial Advisors LLC boosted its stake in shares of Pfizer by 1.6% in the 1st quarter. Delta Financial Advisors LLC now owns 25,266 shares of the biopharmaceutical company’s stock valued at $709,000 after purchasing an additional 398 shares in the last quarter. Finally, Mount Vernon Associates Inc. MD boosted its stake in shares of Pfizer by 1.0% in the 1st quarter. Mount Vernon Associates Inc. MD now owns 41,919 shares of the biopharmaceutical company’s stock valued at $1,177,000 after purchasing an additional 400 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.
Analyst Upgrades and Downgrades
PFE has been the topic of several analyst reports. HSBC upped their target price on shares of Pfizer from $28.00 to $30.00 and gave the stock a “hold” rating in a report on Thursday, September 10th. JPMorgan Chase & Co. boosted their price target on shares of Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research report on Friday, October 9th. Scotiabank upped their price objective on shares of Pfizer from $30.00 to $33.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 6th. BMO Capital Markets dropped their price objective on shares of Pfizer from $34.00 to $30.00 and set an “outperform” rating for the company in a report on Monday, July 13th. Finally, Bank of America cut their target price on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a research note on Friday, July 10th. Five analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $28.65.
Read Our Latest Analysis on PFE
Pfizer Price Performance
Shares of PFE stock opened at $30.48 on Monday. The stock’s fifty day moving average is $28.55 and its 200-day moving average is $26.79. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27. The stock has a market capitalization of $173.73 billion, a PE ratio of 40.11, a PEG ratio of 2.07 and a beta of 0.31. Pfizer Inc. has a 52 week low of $23.62 and a 52 week high of $30.67.
Pfizer (NYSE:PFE – Get Free Report) last announced its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, beating analysts’ consensus estimates of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%. The company had revenue of $15.03 billion during the quarter, compared to analyst estimates of $14.40 billion. During the same period last year, the company posted $0.78 earnings per share. The firm’s quarterly revenue was up 2.6% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities research analysts expect that Pfizer Inc. will post 2.94 EPS for the current fiscal year.
Pfizer Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 7th. Shareholders of record on Friday, November 6th will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, November 6th. This represents a $1.72 dividend on an annualized basis and a yield of 5.6%. Pfizer’s dividend payout ratio is currently 226.32%.
Pfizer News Summary
Here are the key news stories impacting Pfizer this week:
- Positive Sentiment: Pfizer reported that its Phase 3 MagnetisMM-32 trial of ELREXFIO met its primary endpoint in patients with relapsed or refractory multiple myeloma. The result supports another potential growth driver for Pfizer’s oncology portfolio. The FDA also expanded the use of TALZENNA plus XTANDI for certain men with metastatic hormone-sensitive prostate cancer, increasing the commercial opportunity for the combination. Pfizer cancer trial and FDA approval article
- Positive Sentiment: New real-world data from China showed continued momentum for lorlatinib in lung cancer treatment, potentially reinforcing the drug’s adoption and durability outside clinical-trial settings. Lorlatinib China study article
- Positive Sentiment: Pfizer launched a Phase 1 trial for Alzheimer’s candidate PF-08161842, adding a new early-stage asset to its pipeline. Although the program is years from potential commercialization, it gives investors another source of long-term optionality. PF-08161842 Alzheimer’s trial article
- Neutral Sentiment: Investors are focused on Pfizer’s third-quarter earnings report, scheduled for November 3. Attention will center on whether non-COVID products and pipeline progress can offset continuing declines in pandemic-related revenue. Pfizer Q3 earnings outlook article
- Negative Sentiment: Analysts remain cautious ahead of earnings, while commentary highlights that Pfizer’s nearly 6% dividend yield exceeded free cash flow in the prior year. That raises questions about long-term payout coverage, even though the dividend remains attractive to income-focused investors. Pfizer dividend safety article
About Pfizer
Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.
The company’s portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.
Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.
Read More
- Five stocks we like better than Pfizer
- Marvell Eyes a Swing for the AI Networking Fences as Markets Weigh Lumentum Price Tag
- Exxon’s Refining Profits Soared—Did Chevron Get the Same Windfall?
- Eli Lilly’s First Full Medicare Quarter: Is Volume Still Outrunning Price Cuts?
- Oracle’s AI Spending Peak Is in Sight—Can the Stock Recover?
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.
